Clinical Trial News and Research

RSS

Researchers test whether cocktail of vitamins and magnesium help prevent hearing loss

About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.

10 Nov 2008

Ewing sarcoma treatment ineffective, despite promising laboratory data

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults.

10 Nov 2008

Food allergies are on the rise but effective treatment in the pipeline

Experts in the U.S. say food allergies are on the rise and although strict avoidance is currently the only treatment, new effective therapies are currently being developed.

10 Nov 2008

Gene therapy for advanced heart failure shows promising results

Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity.

10 Nov 2008

Can vitamins and minerals prevent hearing loss?

About 10 million people in the United States alone--from troops returning from war to students with music blasting through headphones--are suffering from impairing noise-induced hearing loss.

10 Nov 2008

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

10 Nov 2008

NEI releases complete data from age-related eye disease study

The National Eye Institute (NEI), part of the National Institutes of Health (NIH), announces the release of more than 10 years of data collected during the Age-Related Eye Disease Study (AREDS), which looked at the progression of age-related macular degeneration and age-related cataract in 4,757 adults aged 55 to 80.

10 Nov 2008

Medtronic announces U.S. trial data on transcatheter valve for congenital heart disease

Today at the annual scientific sessions of the American Heart Association, the first U.S. clinical trial data on the Melody transcatheter pulmonary valve were presented. These findings also represent the first U.S. data on transcatheter valves in a population with congenital heart disease and the first reported U.S. data on the use of a transcatheter valve in the pulmonary position. The Melody valve is currently investigational in the U.S.

10 Nov 2008

New risk factor for heart disease suggests more should be on statins

Canadian scientists have discovered a new risk factor for cardiovascular disease and the significance of their discovery was so conclusive that the clinical trial was stopped before its scheduled completion date.New risk factor for heart disease suggests more should be on statins

10 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

High levels of high-sensitivity C-reactive protein found to be new risk factor for cardiovascular disease

A team of international researchers - including scientists from the McGill University Health Centre (MUHC) and McGill University - have discovered that having high levels of particular protein puts patients at increased risk of developing cardiovascular disease.

10 Nov 2008

Stents no help for patients with narrow kidney arteries

Using stents to open up kidney arteries is commonly done in patients with atherosclerotic renovascular disease, but the procedure provides no benefit, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

10 Nov 2008

Spherix starts patient recruitment in India for phase 3 diabetes trial

Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.

8 Nov 2008

Behavioral therapy helps overcome depression in kidney disease patients on dialysis

Depression is common among individuals on dialysis for kidney disease, but behavioral therapy can significantly improve their quality of life, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

8 Nov 2008

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

Novel concept in chronic lymphoid leukemia treatment

Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer.

7 Nov 2008

GSK initiates major seasonal influenza vaccine efficacy trial

GlaxoSmithKline (GSK) announced today that it has started a worldwide clinical efficacy trial to evaluate an innovative vaccine for the prevention of seasonal influenza.

6 Nov 2008

SALVAT submits complete response to FDA approvable letter for CETRAXAL

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).

6 Nov 2008

Nicotinamide, a form of vitamin B3, reduces Alzheimer's symptoms

An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.

5 Nov 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008

Clinical Trial News and Research

Researchers test whether cocktail of vitamins and magnesium help prevent hearing loss

Ewing sarcoma treatment ineffective, despite promising laboratory data

Food allergies are on the rise but effective treatment in the pipeline

Gene therapy for advanced heart failure shows promising results

Can vitamins and minerals prevent hearing loss?

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

NEI releases complete data from age-related eye disease study

Medtronic announces U.S. trial data on transcatheter valve for congenital heart disease

New risk factor for heart disease suggests more should be on statins

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

High levels of high-sensitivity C-reactive protein found to be new risk factor for cardiovascular disease

Stents no help for patients with narrow kidney arteries

Spherix starts patient recruitment in India for phase 3 diabetes trial

Behavioral therapy helps overcome depression in kidney disease patients on dialysis

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Novel concept in chronic lymphoid leukemia treatment

GSK initiates major seasonal influenza vaccine efficacy trial

SALVAT submits complete response to FDA approvable letter for CETRAXAL

Nicotinamide, a form of vitamin B3, reduces Alzheimer's symptoms

Investigational drug, MK-677 shows promise for reducing age-related frailty

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News